IDEAYA Biosciences, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:IDYA) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 1.1 B1.04 B1.19 B1.11 B1.03 B Total liabilities 76.51 M81.62 M93.1 M86.39 M93.08 M Total equity 1.02 B959.65 M1.09 B1.02 B937.27 M Total liabilities & shareholders' equities 1.1 B1.04 B1.19 B1.11 B1.03 B Total debt ————— Net debt —————

News

IDEAYA Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion H2 2026

Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates

Stocks Settle Higher in Hopes for an Agreement to End the Iran War

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma - Slideshow (NASDAQ:IDYA) 2026-04-13

Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality (IDYA)

IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma Transcript

Stocks Recover as Oracle Leads Software Companies Higher

Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma

Stocks Retreat as US Set to Blockade the Strait of Hormuz

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars - IDEAYA Biosciences (NASDAQ:IDYA)

Ideaya Biosciences Stock: Key Pivotal Data Imminent (NASDAQ:IDYA)